Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Long noncoding RNAs (lncRNAs) are recently implicated in modifying immunology in
colorectal cancer (CRC). Nevertheless, the clinical significance of immune-related lncRNAs …

Skin cutaneous melanoma (SKCM, hereafter referred to as melanoma) is the most lethal
skin cancer with increasing incidence. Regulated cell death plays an important role in …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …

Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer.
Therefore, this study was aimed to investigate the genes associated with TME and develop a …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …